Welcome to our dedicated page for Marker Therapeut news (Ticker: MRKR), a resource for investors and traders seeking the latest updates and insights on Marker Therapeut stock.
Marker Therapeutics, Inc. (Nasdaq: MRKR) is a Houston, Texas-based, clinical-stage immuno-oncology company developing multi-antigen recognizing T cell (MAR-T) therapies for hematological malignancies and solid tumors. This news page aggregates company press releases and third-party coverage related to MRKR, with a focus on clinical data, research milestones, and corporate developments.
Investors and followers of MRKR can review updates on the company’s lead program, MT-601, a MAR-T cell product being evaluated in the Phase 1 APOLLO trial for patients with relapsed or refractory lymphoma who have failed or are not candidates for anti-CD19 CAR-T cell therapy. News items include reported objective response rates, safety findings such as the absence of dose-limiting toxicities and ICANS in dose escalation cohorts, and progress into dose expansion in diffuse large B cell lymphoma.
Coverage also highlights Marker’s expansion into additional indications, including a pancreatic cancer program supported by non-dilutive funding and an Off-the-Shelf MAR-T initiative, MT-401-OTS, in the RAPID trial for relapsed acute myeloid leukemia or myelodysplastic syndromes. Readers will find announcements on first-patient dosing, early safety observations, and scientific insights such as the impact of lymphodepletion on MAR-T cell expansion and persistence.
Beyond clinical results, MRKR news includes financial updates, grant awards from U.S. state and federal agencies, collaborations such as the cGMP manufacturing agreement with Cellipont Bioservices for MT-601, participation in investor conferences, and changes in corporate governance and auditors. This page is a resource for tracking how Marker’s MAR-T platform and pipeline evolve over time.
Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, announced that its President and CEO, Peter L. Hoang, will participate in a panel discussion titled, “CAR-T and Beyond: What Are the Next Generation Cell Therapies?” at the Cantor Fitzgerald Cell and Genetic Medicines Conference in New York on September 15, 2022 at 9:20 a.m. ET. This participation highlights the company’s focus on developing innovative T cell-based immunotherapies for treating hematological malignancies and solid tumors, showcasing their commitment to advancing cancer treatment.
Marker Therapeutics (MRKR) reported its Q2 2022 financial results and corporate updates, highlighting progress in its clinical programs for AML and lymphoma. The company received an $8 million upfront payment from Wilson Wolf, aiding its efforts. MT-401, a treatment for AML, continues to show promise with recent patient results. Additionally, the FDA cleared IND applications for MT-601 targeting lymphoma and pancreatic cancer. However, the company implemented a restructuring plan, reducing its workforce by 23.5% to conserve capital. As of June 30, 2022, cash reserves stood at $25.8 million.
Marker Therapeutics (Nasdaq: MRKR) has received FDA clearance for its IND application of MT-601, a novel T cell therapy targeting six tumor-associated antigens. The upcoming Phase 1 trial will focus on patients with relapsed/refractory non-Hodgkin lymphoma who have failed anti-CD19 CAR T therapies. The therapy aims to offer significant advantages, including enhanced durability and reduced severe toxicities compared to traditional CAR-T therapies. The trial highlights a manufacturing process enabling a higher cell dose, which could accelerate treatment timelines and improve patient outcomes.
Marker Therapeutics, Inc. (MRKR) provided a corporate update and Q1 2022 financial results. The company anticipates topline data from its Phase 2 AML trial's Group 2 in Q2 2022. Initial results from the trial showed MRD elimination in one patient. Marker plans to file INDs for its second T cell therapy candidate, MT-601, in lymphoma and pancreatic cancer by the end of 2022, with trials to begin in 2023. As of March 31, 2022, cash reserves were $28.8 million, while R&D expenses rose to $7.0 million, and net loss increased to $9.9 million.
Marker Therapeutics, Inc. (Nasdaq: MRKR) announced the presentation of four posters on its Multi-Tumor-Associated Antigen (MultiTAA)-specific T cell therapies at the 2022 ISCT Annual Meeting in San Francisco from May 4-7, 2022. CEO Peter L. Hoang highlighted improvements in manufacturing processes leading to faster production and enhanced potency, particularly for MT-401 in Phase 2 trials for post-transplant AML. The posters will cover topics including the clinical results from the Phase 2 AML trial and advances in T cell manufacturing technology.
Marker Therapeutics (MRKR) announced a services agreement with Wilson Wolf Manufacturing, featuring an $8 million upfront payment and a potential additional $1 million. This partnership highlights Marker’s expertise in cell therapy manufacturing, allowing it to maintain control and reduce costs. CEO Peter Hoang emphasized the benefits of having in-house production capabilities. The deal is expected to enhance Marker’s operations, particularly in treating hematological and solid tumors, while showcasing Wilson Wolf's confidence in Marker’s technology.
Marker Therapeutics, Inc. (Nasdaq:MRKR) reports completion of patient enrollment in its Phase 2 AML trial for lead product MT-401, with a topline readout anticipated in Q2 2022. The company has developed a new nine-day manufacturing process for T cell therapies, increasing potency and reducing production time. Additionally, plans are in place to file INDs for lymphoma and pancreatic cancer by the end of 2022. However, in 2021, Marker reported a net loss of $41.9 million and increased R&D expenses of $27.8 million, compared to $18.9 million in 2020.
Marker Therapeutics (NASDAQ:MRKR), a clinical-stage immuno-oncology firm, announced that CFO Anthony H. Kim will present at two investor conferences in March 2022. The first is the ROTH Annual Conference on March 14 at 11:00 a.m. ET, followed by the Oppenheimer Virtual Annual Healthcare Conference on March 17 at 10:40 a.m. ET. Webcasts of both presentations will be available on the company's website. Marker is focused on developing non-engineered, tumor-specific T cell therapies for hematological malignancies and solid tumors.
Marker Therapeutics (MRKR) reported positive outcomes from the safety lead-in stage of its Phase 2 AML trial, with no severe adverse effects and one MRD positive patient achieving MRD negativity after treatment with MT-401. The company has developed a new T cell manufacturing process, reducing production time to nine days and enhancing product potency and specificity. Plans include expanding their pipeline into solid tumors like pancreatic cancer, with additional IND filings expected by year-end 2022. A conference call will be held today to discuss these developments further.
Marker Therapeutics, Inc. (Nasdaq:MRKR) announced a conference call and webcast on February 16, 2022, at 5:00 p.m. EST to discuss updates on its clinical programs and pipeline. The event will be accessible via the Investors section of the company's website. Marker specializes in next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, focusing on non-engineered, tumor-specific T cells. The company believes its therapies are easier to manufacture and less toxic than current CAR-T and TCR approaches, potentially providing significant clinical benefits.